(Q45916399)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

0 references

1 reference

chronic lymphocytic leukemia

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Agostino Cortelezzi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Umberto Gianelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Anna Bossi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Gianluigi Reda

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Antonino Neri

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

M C Pasquini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

A Gardellini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

B Sarina

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

W Barcellini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

G L Deliliers

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

30 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

2027-2033

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

New prognostic markers in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Antibody therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Rediscovering alemtuzumab: current and emerging therapeutic roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Pharmacokinetics of alemtuzumab and the relevance in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Stability of alemtuzumab for low-dose induction and test doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.148

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2009.148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641526%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 February 2020

1022346866

0 references

1 reference